Download as PDF, PPTX
Uploaded byfinance13
PDF, PPTX219 views
bristol myerd squibb bristol myerd squibb
Dr. Elliott Sigal presented at the JP Morgan Healthcare Conference on January 14, 2009. He discussed Bristol-Myers Squibb's transition to a next generation biopharma model focused on innovation and partnerships. This model aims to develop treatments for serious unmet medical needs in areas like oncology, immunology, hepatitis C, Alzheimer's, and diabetes. Sigal highlighted several drug candidates in BMS's pipeline and their potential to address key disease areas like HCV, Alzheimer's, diabetes, transplantation, and oncology. He concluded by emphasizing BMS's strong track record of success in bringing new therapies to patients.
